Investigational drug · Phase 3
PF-07275315
Also called: tilrekimig
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
8
8 still active
All registered trials
9
Any phase or sponsor naming "PF-07275315"
First trial start
2023
Aug 22, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PF-07275315", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atopic Dermatitis
- Asthma
- Moderate to Severe Chronic Obstructive Pulmonary Disease
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Asthma · COPD · Immunology and inflammation · Respiratory · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "PF-07275315" as an intervention, largest first.
- A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe EczemaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07783425 · 1,375 participants (planned) · Start Aug 24, 2026 · Primary completion Sep 8, 2028
Drug: Tilrekimig; Dupilumab · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Phoenix, Arizona; Bryant, Arkansas · 50 sites in all
PfizerPfizer (PFE)
NCT07839884 · 1,360 participants (planned) · Start Oct 14, 2026 · Primary completion Apr 21, 2034
Drug: Tilrekimig · For: Moderate to Severe Chronic Obstructive Pulmonary Disease
Sites: San Diego, California; Winston-Salem, North Carolina; DuBois, Pennsylvania
- A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07363694 · 1,156 participants (planned) · Start Feb 11, 2026 · Primary completion Oct 24, 2030
Drug: PF-07275315 dose 1; PF-07275315-dose 2 and 2 more · For: Moderate to Severe Chronic Obstructive Pulmonary Disease
Sites: Birmingham, Alabama; Dothan, Alabama; Mobile, Alabama · 189 sites in all
- A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe AsthmaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07869043 · 1,100 participants (planned) · Start Sep 30, 2026 · Primary completion Jun 7, 2029
Drug: tilrekimig · For: Asthma
Sites: River Forest, Illinois; Hannibal, Missouri; The Bronx, New York · 12 sites in all
- A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT05995964 · 507 participants · Start Aug 22, 2023 · Primary completion Nov 12, 2026
Drug: PF-07275315; PF-07264660 · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Peoria, Arizona; Phoenix, Arizona · 96 sites in all
- A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe EczemaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07765888 · 375 participants (planned) · Start Aug 17, 2026 · Primary completion Mar 10, 2028
Drug: Tilrekimig; Placebo · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Scottsdale, Arizona; Bakersfield, California · 23 sites in all
- A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe AsthmaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT06977581 · 252 participants (planned) · Start May 20, 2025 · Primary completion Mar 8, 2027
Drug: PF-07275315 · For: Asthma
Sites: Mobile, Alabama; Chandler, Arizona; Lancaster, California · 137 sites in all
PfizerPfizer (PFE)
NCT05411588 · 65 participants · Start Jun 9, 2022 · Primary completion May 13, 2024
Drug: PF-07275315; Placebo · For: Healthy Volunteers
Sites: Lake Forest, California; Tustin, California; New Haven, Connecticut · 5 sites in all
- A Study to Learn More About the Study Medicine PF-07275315 in Healthy Chinese Adult ParticipantsCompleted
PfizerPfizer (PFE)
NCT06675188 · 13 participants · Start Jan 6, 2025 · Primary completion Jul 14, 2025
Drug: PF-07275315 · For: Healthy
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Atopic Dermatitis
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
- ICP-332Phase 34 trials
Beijing InnoCare Pharma Tech Co., Ltd. · Non Segmental Vitiligo, Chronic Spontaneous Urticaria (CSU), Atopic Dermatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.